NCT07542327Not yet recruiting
The Role of Autoantibodies Against G-protein Coupled Receptors in Obesity
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to explore if GPCR-autoantibodies: 1. are pressent in people living with obesity, and are associated with degree of obesity 2. if it is associated with obesity related diseases
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 160 (estimated)
- First submitted
- 14 Apr 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- Claus Bogh Juhl
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07542327
What you commit to
- Study type: Observational
- Planned participants: 160
- From 1 Sept 2026 to the primary completion date, 1 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- individuals previously treated with GLP-1RA medication for any indication
- Individuals who have previously undergone bariatric surgery
Other illness
- Individuals with type 1 diabetes
Who the study is looking for
- Inhabitant in the Region of Southern Denmark
- BMI above 30kg/m2
- age between 18 and 60 years.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Southern Denmark, Esbjerg Coordinator of this site? Confirm its status | Esbjerg | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.